CTDSP1

Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 · Q9GZU7 · CTDSP1 on Sugi Atlas →

127,923 patent compounds predicted against CTDSP1, 93,123 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL46257	0.76	5/20
SCHEMBL64694	0.61	4/20
Oxapium (SCHEMBL24857)	0.47	4/20
SCHEMBL14751	0.84	3/20
Cefuroxime Axetil (SCHEMBL41099)	0.76	3/20
SCHEMBL46577	0.65	3/20
SCHEMBL46575	0.59	3/20
Ceforanide (SCHEMBL122072)	0.57	3/20
Ceftezole (SCHEMBL147529)	0.52	3/20
SCHEMBL8427	0.50	3/20
SCHEMBL41100	0.49	3/20
SCHEMBL128077	0.43	3/20
SCHEMBL12076	0.43	3/20
Cephalothin (SCHEMBL2990)	1.00	2/20
Cephalothin (SCHEMBL148784)	0.98	2/20
Cefuroxime (SCHEMBL40413)	0.86	2/20
Cefuroxime (SCHEMBL40414)	0.86	2/20
Cefuroxime (SCHEMBL40415)	0.86	2/20
Cefuroxime (SCHEMBL41261)	0.84	2/20
Cefuroxime (SCHEMBL123194)	0.84	2/20

Clinical trials — most relevant to CTDSP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas	PHASE1/PHASE2	RECRUITING
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema	PHASE2	COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	PHASE2	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	PHASE1	COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia	nan	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients	nan	UNKNOWN
Genetic of SportS Induced Endofibrotic Remodeling	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification	nan	RECRUITING
iSITE: Investigation of Somatic Alterations in Tumours of the Eye	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CTDSP1 binder may also engage these)

Protein	Name	Similarity
O14595	—	1.000	O14595 →
P58465	—	1.000	P58465 →
P58466	—	1.000	P58466 →
O15194	—	0.995	O15194 →
Q8BX07	—	0.993	Q8BX07 →
Q9PTJ6	—	0.989	Q9PTJ6 →
Q09695	—	0.984	Q09695 →
Q801R4	—	0.979	Q801R4 →
O08605	—	0.979	O08605 →
Q8LI34	—	0.978	Q8LI34 →
Q03145	—	0.978	Q03145 →
Q5XIK8	—	0.978	Q5XIK8 →
Q9DBN9	—	0.978	Q9DBN9 →
Q0E2Z7	—	0.978	Q0E2Z7 →
Q75LI2	—	0.978	Q75LI2 →
Q08BB5	—	0.978	Q08BB5 →
DGKG	Diacylglycerol kinase gamma	0.977	landscape →
D3ZEY4	—	0.977	D3ZEY4 →
P08413	—	0.977	P08413 →
Q4Q089	—	0.977	Q4Q089 →
O94910	—	0.977	O94910 →
Q9D1P2	—	0.977	Q9D1P2 →
Q13415	—	0.977	Q13415 →
A4QNX6	—	0.976	A4QNX6 →
O19111	—	0.976	O19111 →
B5MCN3	—	0.976	B5MCN3 →
Q9N4V4	—	0.976	Q9N4V4 →
P92981	—	0.976	P92981 →
F4IM84	—	0.976	F4IM84 →
Q8GVC7	—	0.976	Q8GVC7 →